Xinan Sheng

Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy

Toripalimab in patients with previously treated advanced upper tract urothelial carcinoma: a subgroup analysis of the phase II POLARIS-03 trial.

A phase II peri-operative study of pembrolizumab plus lenvatinib for mucosal melanoma.

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer

Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib/II dose-escalation and dose-expansion study.

Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer.

Oncolytic virus OH2 extends survival in patients with PD-1 pretreated melanoma: phase Ia/Ib trial results and biomarker insights.

Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study.

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial

Nectin-4 targeted ADC, SHR-A2102, in patients with advanced or metastatic urothelial carcinoma: A phase 1 study.

Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets.

Neoadjuvant toripalimab plus nimotuzumab combined with taxol-based chemotherapy in locally advanced penile squamous cell carcinoma.

First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.

Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian.

Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.

MARCO+ Tumor-Associated Macrophages Impede CD8+ T Cell Immunity to Facilitate Immunotherapy Resistance in Renal Cell Carcinoma.

Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.

Predominance of hyperprogression in mucosal melanoma during anti-PD-1 monotherapy treatment.

Real-World Efficacy and Safety of Anti-PD-1 Antibody Plus Apatinib and Temozolomide for Advanced Acral Melanoma.

Dynamic Change of PD-L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti-PD-1 Therapy.

Advances in antibody-drug conjugates for urothelial carcinoma treatment.

Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer.

Clinical Characteristics and Impact on Prognosis of Melanoma Accompanied by Multiple Primary Malignancies: A Retrospective Analysis.

A prognostic model for survival of patients with metastatic upper tract urothelial carcinoma with first-line systemic therapy.

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Supplementary Figures S1-S15 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Supplementary Methods S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma

Supplementary Table S3 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma